HC Wainwright Estimates Cabaletta Bio Q1 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Cabaletta Bio in a research report issued on Wednesday, April 1st. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.37) for the quarter. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.37) EPS and FY2030 earnings at $1.11 EPS.

Several other analysts have also recently weighed in on CABA. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of Cabaletta Bio from a “strong sell” rating to a “hold” rating in a report on Sunday, March 29th. Guggenheim lifted their price target on shares of Cabaletta Bio from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Morgan Stanley decreased their price objective on Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Tuesday, March 24th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Cabaletta Bio Price Performance

Shares of CABA stock opened at $2.96 on Thursday. The firm’s 50-day moving average is $2.93 and its two-hundred day moving average is $2.58. Cabaletta Bio has a 12 month low of $0.99 and a 12 month high of $3.78. The company has a market capitalization of $329.51 million, a PE ratio of -1.30 and a beta of 3.30.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.05.

Insider Buying and Selling at Cabaletta Bio

In other Cabaletta Bio news, Director Mark Simon bought 11,061 shares of Cabaletta Bio stock in a transaction on Wednesday, January 21st. The shares were bought at an average cost of $2.28 per share, for a total transaction of $25,219.08. Following the acquisition, the director directly owned 147,205 shares in the company, valued at $335,627.40. This represents a 8.12% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Shawn Tomasello purchased 22,725 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was acquired at an average cost of $2.21 per share, with a total value of $50,222.25. Following the transaction, the director directly owned 22,725 shares in the company, valued at $50,222.25. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 127,668 shares of company stock worth $286,211. 11.25% of the stock is currently owned by company insiders.

Institutional Trading of Cabaletta Bio

Several hedge funds have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. boosted its holdings in Cabaletta Bio by 17.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock valued at $21,590,000 after purchasing an additional 1,495,768 shares during the period. Invesco Ltd. grew its stake in Cabaletta Bio by 54.1% during the 4th quarter. Invesco Ltd. now owns 189,195 shares of the company’s stock worth $414,000 after purchasing an additional 66,395 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Cabaletta Bio during the 4th quarter worth about $58,000. KVP Capital Advisors LP purchased a new stake in Cabaletta Bio during the 4th quarter worth about $1,107,000. Finally, Ikarian Capital LLC acquired a new stake in Cabaletta Bio in the 4th quarter valued at about $1,971,000.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.